Baidu
map

Cell Death Differ:CHIP介导CIB1泛素化调节肺腺癌的上皮-间质转化进程和肿瘤的转移

2020-10-30 xiaozeng MedSci原创

肺癌作为最常见的恶性肿瘤之一,对人类的健康构成了严重威胁。在过去的几十年中,肺腺癌(LAC)是最常见的病理类型,其发病率仍在激增。LAC的预后较差,其5年生存率仅约15%,5年复发率约为30%,且其相

肺癌作为最常见的恶性肿瘤之一,对人类的健康构成了严重威胁。在过去的几十年中,肺腺癌(LAC)是最常见的病理类型,其发病率仍在激增。LAC的预后较差,其5年生存率仅约15%,5年复发率约为30%,且其相关分子机制仍知之甚少。因此,探索LAC的分子机制并寻找潜在的治疗靶标则显得尤为重要。

CIB1(人钙-整合素结合蛋白1)是调节细胞粘附、迁移和分化的钙调蛋白的同源物,被认为在许多肿瘤细胞中充当癌基因的功能。然而其在LAC中的作用还有待研究。

CIB1在LAC组织和细胞中上调,且与患者的不良预后相关

该研究通过免疫组化技术检测LAC组织及其邻近正常组织中CIB1的表达水平,并分析CIB1的表达水平与患者临床病理特征的关系。并检测CIB1对LAC细胞的上皮-间质转化(EMT)作用、细胞迁移和转移的影响。研究人员采用LS-MS质谱分析法鉴定与CIB1相互作用的蛋白质。

上调CHIP表达减轻CIB1诱导的LAC迁移和转移能力

研究人员发现,在LAC组织和细胞系中CIB1的表达水平上调,且与临床病理特征和患者的不良预后相关。CHIP是一种泛素E3连接酶,可以促进CIB1的多泛素化并通过蛋白酶体途径降解CIB1。此外,CIB1的第10位和第65位赖氨酸残基是CIB1的泛素化位点。研究人员发现,CHIP介导的CIB1表达水平下调对于抑制LAC的转移和迁移至关重要。


综上,这些研究结果表明,CHIP介导的CIB1泛素化可以调节LAC中的上皮-间质转化进程和肿瘤转移。


原始出处:

Liu, Y., Zhou, Y., Zhang, P. et al. CHIP-mediated CIB1 ubiquitination regulated epithelial–mesenchymal transition and tumor metastasis in lung adenocarcinoma. Cell Death Differ (20 October 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962337, encodeId=31b3196233e02, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 16 10:27:55 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928021, encodeId=b9d2192802161, content=<a href='/topic/show?id=6d3c469e64' target=_blank style='color:#2F92EE;'>#CIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4697, encryptionId=6d3c469e64, topicName=CIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sat Jun 05 09:27:55 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872035, encodeId=068118e2035df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 14:27:55 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531687, encodeId=501b153168e39, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Oct 31 15:27:55 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784227, encodeId=f7ea1e8422790, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sun Jun 20 04:27:55 CST 2021, time=2021-06-20, status=1, ipAttribution=)]
    2021-09-16 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962337, encodeId=31b3196233e02, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 16 10:27:55 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928021, encodeId=b9d2192802161, content=<a href='/topic/show?id=6d3c469e64' target=_blank style='color:#2F92EE;'>#CIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4697, encryptionId=6d3c469e64, topicName=CIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sat Jun 05 09:27:55 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872035, encodeId=068118e2035df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 14:27:55 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531687, encodeId=501b153168e39, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Oct 31 15:27:55 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784227, encodeId=f7ea1e8422790, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sun Jun 20 04:27:55 CST 2021, time=2021-06-20, status=1, ipAttribution=)]
    2021-06-05 yangeasy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962337, encodeId=31b3196233e02, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 16 10:27:55 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928021, encodeId=b9d2192802161, content=<a href='/topic/show?id=6d3c469e64' target=_blank style='color:#2F92EE;'>#CIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4697, encryptionId=6d3c469e64, topicName=CIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sat Jun 05 09:27:55 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872035, encodeId=068118e2035df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 14:27:55 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531687, encodeId=501b153168e39, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Oct 31 15:27:55 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784227, encodeId=f7ea1e8422790, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sun Jun 20 04:27:55 CST 2021, time=2021-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962337, encodeId=31b3196233e02, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 16 10:27:55 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928021, encodeId=b9d2192802161, content=<a href='/topic/show?id=6d3c469e64' target=_blank style='color:#2F92EE;'>#CIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4697, encryptionId=6d3c469e64, topicName=CIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sat Jun 05 09:27:55 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872035, encodeId=068118e2035df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 14:27:55 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531687, encodeId=501b153168e39, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Oct 31 15:27:55 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784227, encodeId=f7ea1e8422790, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sun Jun 20 04:27:55 CST 2021, time=2021-06-20, status=1, ipAttribution=)]
    2020-10-31 cy0328
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962337, encodeId=31b3196233e02, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 16 10:27:55 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928021, encodeId=b9d2192802161, content=<a href='/topic/show?id=6d3c469e64' target=_blank style='color:#2F92EE;'>#CIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4697, encryptionId=6d3c469e64, topicName=CIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sat Jun 05 09:27:55 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872035, encodeId=068118e2035df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 17 14:27:55 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531687, encodeId=501b153168e39, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Oct 31 15:27:55 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784227, encodeId=f7ea1e8422790, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sun Jun 20 04:27:55 CST 2021, time=2021-06-20, status=1, ipAttribution=)]
    2021-06-20 isabellayj

相关资讯

Cell Death Dis:circRNA-002178充作ceRNA促进肺腺癌PDL1/PD1表达

肺癌是全球癌症相关死亡的主要原因之一。根据组织学类型及预后情况分析,肺腺癌(LUAD)占所有类型肺癌的约50%,且逐年增加,尤其是在女性及年轻人中。尽管目前的诊断及治疗有所改善,但LUAD的5年生存率

Nat Commun :重大进展!中山大学蔡俊超/吴珏珩发现肺腺癌新的潜在治疗靶标

尽管AKT过度活化在肿瘤进展中很重要,但是各种AKT抑制剂的临床试验结果仍然不是最佳的,这表明需要进一步了解AKT驱动的肿瘤转移。

Nat Commun:MCL-1或可成为肺腺癌的潜在治疗靶标

肺癌作为最常被诊断的癌症,是全球范围内癌症相关死亡的主要原因之一。肺癌在组织学上分为小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC),后者约占总病例的85%。肺腺癌(LUAD)和肺鳞状细胞癌(LUS

Cell:重大进展,中国科学家首次揭示肺腺癌蛋白质组完整图谱

导言:肺癌是发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤之一。而肺腺癌(LUAD)约占肺癌总数的一半。近日,来自中科院等国内多家机构的科学家首次在国际上揭示了肺腺癌蛋白质组完整图谱,为肺

女性,发现双下肢水肿2月,右侧胸痛1月,请诊断!

女性,发现双下肢水肿2月,右侧胸痛1月,请诊断!

肺腺癌乳腺转移超声及MRI表现1例

病例女,34岁。主诉“肺腺癌靶向治疗5月余,左乳腺疼痛1周”入院。既往病史:无。查体:左侧乳腺乳头凹陷,左侧乳腺外上象限触及弥漫性肿块,质稍硬,边界不清;右侧乳房外形正常,皮肤

Baidu
map
Baidu
map
Baidu
map